FDA panel rejects Otsuka’s tolvaptan; liver risk too concerning
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical was not able to convince FDA expert advisers on 5 August the firm's risk evaluation and mitigation strategy (REMS) plan would be enough to overcome the potential that patients taking tolvaptan would be exposed to liver injury.